<DOC>
	<DOCNO>NCT02039895</DOCNO>
	<brief_summary>Radiation therapy , Total skin electron beam therapy ( TSEBT ) , achieve high response rate effective treatment cutaneous T-cell lymphoma affect superficial region . One widely use TSEBT technique consist six dual field initially develop Stanford University . However , deviation occur prescription dose 40 % surface dose inhomogeneity much 90 % body area perineum eyelid . Helical tomotherapy ( HT ) advantage irradiate extend volume treatment length 160 cm , continuously helical pattern without need field junction . Using HT , image-guided intensity-modulated radiotherapy , replace conventional TSEBT technique increase dose delivery decrease toxicities possibly . Recently , publish possibility helical irradiation total skin ( HITS ) physical proving show clinical result HITS successfully woman T cell lymphoma failure chemotherapy , topic UV irradiation local radiotherapy ( RT ) overcome surface dose inhomogeneity conventional RT . Here , investigator enroll stage I-IV cutaneous T-cell lymphoma ( CTCL ) International Society Cutaneous Lymphomas ( ISCL ) /U.S . Cutaneous Lymphoma Consortium ( USCLC ) /European Organization Research &amp; Treatment Cancer ( EORTC ) , patient candidate TSEBT recommendation National Comprehensive Cancer Network Guidelines ( Version 4.2011 , Mycosis fungoid/Sezary syndrome ) refractory feasible topic UV irradiation , Interferon alpha , psoralen plus ultraviolet A photochemotherapy , Accutane® ( Isotretinoin ) chemotherapy receive HITS replace TSEBT . Additionally , compare advantage disadvantage plan HT conventional RT TSEBT .</brief_summary>
	<brief_title>Helical Irradiation Total Skin ( HITS ) Cutaneous Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>1 . The stage IIV cutaneous Tcell lymphoma ( CTCL ) International Society Cutaneous Lymphomas ( ISCL ) U.S. Cutaneous Lymphoma Consortium ( USCLC ) /European Organization Research &amp; Treatment Cancer ( EORTC ) , patient candidate TSEB recommendation National Comprehensive Cancer Network Guidelines ( Version 4.2011 , Mycosis fungoid/Sezary syndrome ) 2 . Patients refractory feasible topic UV irradiation , Interferon alpha , psoralen plus ultraviolet A photochemotherapy , Isotretinoin chemotherapy . 3 . Eligibility criterion include follow : Karnofsky status 70 % great ; creatinine clearance great 50 mL/min ; cardiac leave ventricular ejection fraction 50 % great ; aspartate aminotransferase alanine aminotransferase less 2.5 time upper limit institutional normal ; adequate pulmonary function show forced expiratory volume great 60 % ; peripheral neuropathy grade 1 low . Patients preassessed ability lie supine approximately 1 hour . 4 . They previously untreated TSEBT . Prior local radiation permit . 5 . All patient voluntarily sign informed consent form approve Institutional Review Board . 1 . Patient prior treat TSEBT CTCL , another type cancer , abnormal cardiac function ( systolic ejection fraction &lt; 50 percent abnormal stress test ) , chronic respiratory disease ( vital capacity carbon monoxide diffusion , &lt; 50 percent normal ) , abnormal liver function ( serum bilirubin , &gt; 2.0 mg per deciliter [ &gt; 35 micromol per liter ] ; serum aminotransferase value four time normal value ) , psychiatric disease . 2 . Females pregnant/lactating planning pregnant . 3 . Patients systemic disease require longterm ( ≥ 2 week ) usage glucocorticosteroid immunosuppressant agent ( ) within 4 week prior initiation study treatment . 4 . Child handicap exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cutaneous T-cell lymphoma</keyword>
	<keyword>Helical irradiation total skin</keyword>
	<keyword>Refractory</keyword>
	<keyword>Total skin electron beam therapy</keyword>
</DOC>